Orrick Advises DURECT on $15 Million Registered Direct Offering


Orrick represented DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing therapeutics based on its epigenetic regulator program and proprietary drug delivery platforms, in its registered direct offering of 29,000,000 shares of common stock for net proceeds of approximately $15 million. The offering closed on June 24, 2019.

The Orrick team consisted of Technology Companies Group partner Stephen Thau, capital markets partner Andrew Thorpe and associates Kenneth Marx, Vinella Sido and Ahalya Hildreth, among others.